<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01619345</url>
  </required_header>
  <id_info>
    <org_study_id>NN9924-3957</org_study_id>
    <secondary_id>2011-004162-14</secondary_id>
    <secondary_id>U1111-1123-7450</secondary_id>
    <nct_id>NCT01619345</nct_id>
  </id_info>
  <brief_title>Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects</brief_title>
  <official_title>Pharmacoscintigraphic Investigation NN9924 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to investigate whether the volume
      of water administered with NN9924 affects the anatomical location (stomach or proximal small
      bowel) of tablet erosion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anatomical location (stomach or proximal small bowel) of tablet at complete tablet erosion (CTE)</measure>
    <time_frame>Assessed 0-4 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the NN9924 concentration curve</measure>
    <time_frame>From time 0-24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anatomical location of initial tablet erosion (ITE)</measure>
    <time_frame>Assessed 0-4 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ITE</measure>
    <time_frame>Assessed 0-4 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to CTE</measure>
    <time_frame>Assessed 0-4 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Period 1: NN9924 with 50 mL water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2: NN9924 with 240 mL water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Subjects will be treated with two single doses of 10 mg semaglutide in a tablet. Dosing will be done on 2 dosing visits separated by 4 to 6 weeks.</description>
    <arm_group_label>Period 1: NN9924 with 50 mL water</arm_group_label>
    <arm_group_label>Period 2: NN9924 with 240 mL water</arm_group_label>
    <other_name>NN9924</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good general health

          -  Body mass index (BMI) of 18.5-30.0 kg/m^2 (both inclusive)

        Exclusion Criteria:

          -  Males who are not willing to use two acceptable forms of highly effective
             contraception

          -  Participation in another clinical trial within 90 days

          -  Any chronic disorder or severe disease

          -  Use of GLP-1 (glucagon-like peptide-1) agonists within 3 months preceding dosing

          -  Subjects who are smokers

          -  Subjects who have donated any blood or plasma in the past month or in excess of 500 mL
             within the 12 weeks preceding screening
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2012</study_first_submitted>
  <study_first_submitted_qc>June 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2012</study_first_posted>
  <last_update_submitted>February 20, 2015</last_update_submitted>
  <last_update_submitted_qc>February 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

